Casadale moreno baji

Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate

Por um escritor misterioso
Last updated 17 novembro 2024
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
BIRB 796 (Doramapimod) P38 MAPK inhibitor,cell permeable and
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Molecules, Free Full-Text
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
p38 MAP kinases: key signalling molecules as therapeutic targets
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Full article: A patent review of MAPK inhibitors (2018 – present)
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
PDF] Structure-based design, synthesis, and biological evaluation
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
PDF) Pyrazolo-pyrimidines: A novel heterocyclic scaffold for
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One
Recomendado para você
você pode gostar

© 2014-2024 phtarkwa.com. All rights reserved.